Cor­rect­ed: BeiGene builds out long-term case for Brukin­sa in CLL with three-year fol­low-up da­ta

Ed­i­tor’s note: A pre­vi­ous ver­sion of this sto­ry mis­char­ac­ter­ized over­all sur­vival da­ta from the ALPINE study as hav­ing “missed” sta­tis­ti­cal sig­nif­i­cance and over­stat­ed the end­point …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER